ClinicalTrials.gg
RecruitingNCT06692049DSDUpdated Sep 3, 2026

Gonadal Tissue Cryopreservation for Fertility Preservation in Children With a Disorder of Sex Development

An observational study in DSD, 46,XY, DSD, Ovotesticular and DSD, Sex Chromosome, sponsored by Erin Rowell. Recruiting at 1 site in United States. Open to participants aged Up to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Erin Rowell · Observational

From the registry’s dates

  • Started Apr 2018; still recruiting 8 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
Up to 30 Years
Sex
All
01

Study summary

The purpose of this study is to offer gonadal tissue freezing and storage to children who are diagnosed with a disorder of sex development (DSD), who are at increased risk of infertility and certain malignancies (cancer). This study involves the storage of gonadal tissue that is being removed for medical reasons (e.g. prevention of cancer development). It includes the processing and freezing of this gonadal tissue, hopefully for potential future use. The tissue will then be stored long-term until the child wishes to try to use the tissue.

Read the detailed description

DSD are conditions in which there is incongruence in an individual's chromosomal, gonadal, or phenotypic sex (refers to sex as determined by an individual's internal or external genitalia and expression of secondary sex characteristics).Different DSD diagnoses have varying degrees of risk for future malignancy. The treating doctor has or will discuss with the participant the risk of developing cancer due to the child's specific diagnosis, and help decide whether this option is in the best interest of the child, and if there are other options to consider (e.g. leaving gonadal tissue in place and monitoring for development of malignancy). If the participant and family have decided to move forward with removal of gonadal tissue for this clinical reason, they will be asked if they would like to have the child participate in this study.

This study seeks to find out if removing gonadal tissue in adolescents and children at risk for losing fertility potential (the ability to have children) and who are scheduled to receive a gonadectomy (removal of gonads) for clinical purposes may preserve, or keep, their ability to have children in the future. Additionally, a primary objective of this study is to use donated research tissue to study long-term ways to preserve and restore reproductive function for children diagnosed with a DSD. Gonadal tissue cryopreservation in patients diagnosed with a DSD is still considered experimental. There have been no reported live births or pregnancies in this population following gonadal tissue cryopreservation at this time.

02

Conditions studied

  • DSD, 46,XY
  • DSD, Ovotesticular
  • DSD, Sex Chromosome
  • Disorders of Sex Development
  • Disorder of Sex Development, 46,XY
  • Disorder of Sex Development, 46,Xy, Cbx2-Related

Keywords

  • DSD
  • GTC
  • Gonadectomy
  • Cryopreservation
  • Fertility Preservation
03

In context

Disorders of Sex Development

32 studies on the registry are indexed under Disorders of Sex Development; 7 are open to participants now.

This study's planned enrollment of 250 is above the median of 84 across 17 observational studies indexed under Disorders of Sex Development.

Browse Disorders of Sex Development studies →

Lead sponsor

Erin Rowell is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children diagnosed with a disorder of sex development who have any risk for malignancy in their gonadal tissue or will have their gonads removed for another clinical indication

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individual \< 30 years of age
  • Children diagnosed with a disorder of sex development who have any risk for in their gonadal tissue or will have their gonads removed for another clinical indication

Exclusion criteria

Exclusion Criteria:

  • Pregnant children
  • Patients likely to retain inherent fertility and reproductive function
  • Children deemed high risk for perioperative complications
  • Patients 12-18 unable to provide assent (i.e. significant psychiatric problems/cognitive delay)
  • Patients 18 and older unable to provide consent (i.e. significant psychiatric problems/cognitive delay)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Disorders of Sex Development (DSD)

    The study seeks to find out if removing gonadal tissue in adolescents and children at risk for losing fertility potential (the ability to have children) and who are scheduled to receive a gonadectomy (removal of gonads) for clinical purposes may preserve, or keep, their ability to have children in the future. Additionally, donated research tissue would be used to study long-term ways to preserve and restore reproductive function of children diagnosed with DSD

    Procedure: Gonadectomy

Interventions

  • ProcedureGonadectomy

    Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation

06

What researchers measure

Primary outcomes

  1. Gonadal Tissue Cryopreservation for Fertility Preservation in Children with Disorders of Sex Development

    The primary outcome is to evaluate the presence of viable germs cells based on histologic evaluation of the gonads for number of germ cells per high power field and to cryopreserve the tissue.

    Time frame: 3 months

Secondary outcomes

  1. Gonadal Tissue Cryopreservation for Fertility Preservation in Children with Disorders of Sexual Development (DSD)

    Secondary outcomes: 1\. Utilize donated research tissue biopsy to establish and investigate technologies that will enable long-term preservation of reproductive function in patients with DSD. In particular the tissue will be used to optimize techniques for freezing and thawing of gonadal tissue for use in tissue transplant, in-vitro follicle maturation, or obtaining spermatogonial stem cells.

    Time frame: yearly, up to 20 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2018 (actual). Primary completion is estimated for Dec 2030, 152 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2020
First posted
Nov 18, 2024
StartActual
Apr 4, 2018
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06692049
Lead sponsor
Erin Rowell
Responsible party
Erin Rowell (Director, Fertility & Hormone Preservation & Restoration, Ann & Robert H Lurie Children's Hospital of Chicago) — Sponsor-investigator
First posted
Nov 18, 2024
Start date
Apr 4, 2018
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Sep 3, 2026

Study contacts

Sara Reyes
Contact
FertilityPreservation@luriechildrens.org
3122274145
Erin Rowell, MD
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion